← Back
No items found.
April 14, 2021

A stronger team

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.

For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.

With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047

April 14, 2021

A stronger team

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.

For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.

With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047

Author:

Per von Mentzer

Author:

Per von Mentzer

In memory of Hans G.

Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.

Read more →

Patent granted in China

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.

Read more →

New board member

PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.

Read more →

22 MSEK new funding

PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map